Transgene
Strasbourg, France · Biotechnology, Health Care, Therapeutics
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses with the goal of indirectly or directly killing cancer cells.
Key facts
- Headquarters
- Strasbourg, France
- Employees
- 51
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- www.transgene.fr
- Company page
Recent activity at Transgene
- : Transgene Appoints Anne Stehlin as Chief Quality Officer
- : Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line.
- : Transgene and ProBioGen Enter Partnership for Cancer Vaccine Development
- : Transgene and ProBioGen Enter License Agreement for Individualized Cancer Vaccine Development
- : Transgene appoints Lucie Larguier as Chief Financial Officer and promotes Christelle Schwoerer to Chief Human Resources Officer
- : Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
Leadership
- Anne Stehlin, Chief Quality Officer
- Christelle Schwoerer, Chief Human Resources Officer
- Lucie Larguier, Chief Financial Officer
- James Wentworth, Chief Business Officer
Verified email and direct lines for Transgene’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Transgene in the news
- Heritable transgenic schistosomes as a living platform for SARS-CoV-2 neutralizing antibody secretion - Nature (Aug 26, 2026)
- Recent advances in site-specific transgene insertion into the maize genome using recombinases and genome editing endonucleases - Frontiers (Dec 01, 2025)
- Transgene and NEC announce preliminary data from Phase I studies of TG4050: Press Releases - NEC (Nov 23, 2021)
- Transgene Successfully Completes a Fundraising of c. €105 Million - GlobeNewswire (Nov 26, 2025)
- Opportunities and Obstacles for Personalized Cancer Vaccines - BioProcess International (Mar 24, 2025)
- An Agrobacterium -mediated base editing approach generates transgene-free edited banana - Wiley & Sons (Apr 01, 2025)
- Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris - GlobeNewswire (Nov 25, 2025)
- Transgene and NEC Bio Prepare Next Steps of TG4050 Development for Cancer Treatment: Press Releases - NEC (Apr 02, 2026)
Companies similar to Transgene
- Jasper Therapeutics · Biotechnology, Health Care, Therapeutics
- Redx Pharma · Biotechnology, Health Care, Therapeutics
- Omnio · Biotechnology, Health Care, Therapeutics
- BioAtla · Biotechnology, Health Care, Therapeutics
- Genetix Biotherapeutics · Biotechnology, Health Care, Therapeutics
About Transgene: questions and answers
What does Transgene do?
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses with the goal of indirectly or directly killing cancer cells.
Where is Transgene headquartered?
Transgene is headquartered in Strasbourg, France.
How many employees does Transgene have?
Transgene has about 51 employees.
What is the latest news on Transgene?
On Oct 14, 2026, Transgene Appoints Anne Stehlin as Chief Quality Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy